Evidence map›Paper›PMID 28405170›Full record

ReviewPharmacogenomics and personalized medicine2017

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals.

Julieta Trinks, Mariela Caputo, María L Hulaniuk, Daniel Corach, Diego Flichman

Abstract readReview
In one paragraph

Review in Pharmacogenomics and personalized medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Julieta TrinksBasic Science and Experimental Medicine Institute (ICBME), University Institute of the Italian Hospital of Buenos Aires; Scientific and Technological National Research Council (CONICET).
Mariela CaputoScientific and Technological National Research Council (CONICET); Servicio de Huellas Digitales Genéticas, Facultad de Farmacia y Bioquímica.
María L HulaniukBasic Science and Experimental Medicine Institute (ICBME), University Institute of the Italian Hospital of Buenos Aires.
Daniel CorachScientific and Technological National Research Council (CONICET); Servicio de Huellas Digitales Genéticas, Facultad de Farmacia y Bioquímica.
Diego FlichmanScientific and Technological National Research Council (CONICET); Cátedra de Virología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because their use may lead to excellent cure rates with fewer side effects. In Latin America, the high prevalence of HCV genotype 1 infection and the significant association of Native American ancestry with risk predictive single-nucleotide polymorphisms (SNPs) in

Indexed as

DAAshepatitis C virusLatin AmericaPEG-IFN/RBVpharmacogenomics

Identifiers

PMID28405170
PMCPMC5378445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.